Clinical data | |
---|---|
Trade names | Glurenorm |
AHFS/ Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral ( tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High ( Tmax = 2–3 hours) |
Metabolism | Extensive hepatic |
Onset of action | 1–1.5 hours |
Excretion | Biliary (95%), renal (5%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.046.770 |
Chemical and physical data | |
Formula | C27H33N3O6S |
Molar mass | 527.64 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Gliquidone ( INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. [1] It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy. [2]
Clinical data | |
---|---|
Trade names | Glurenorm |
AHFS/ Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | Oral ( tablets) |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | High ( Tmax = 2–3 hours) |
Metabolism | Extensive hepatic |
Onset of action | 1–1.5 hours |
Excretion | Biliary (95%), renal (5%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
ECHA InfoCard | 100.046.770 |
Chemical and physical data | |
Formula | C27H33N3O6S |
Molar mass | 527.64 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Gliquidone ( INN, sold under the trade name Glurenorm) is an anti-diabetic medication in the sulfonylurea class. [1] It is classified as a second-generation sulfonylurea. It is used in the treatment of diabetes mellitus type 2. It is marketed by the pharmaceutical company Boehringer Ingelheim (Germany).
Gliquidone is fully metabolized by the liver. Its metabolites are excreted virtually completely with bile (even with long-term administration), thus allowing the use of medication in diabetic patients with kidney disease and diabetic nephropathy. [2]